Related Experiment Video
Updated: Oct 17, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Effect of misonidazole pretreatment on nitrogen mustard-induced DNA cross-linking in mouse tissues in vivo
Abstract:
In the present study we have used the alkaline elution technique to study the effect of misonidazole (MISO) on the initial amount of DNA cross-linking in various normal and neoplastic tissues of C3H mice treated with nitrogen mustard (HN2) in vivo. Tissue samples for analysis of the cross-links were prepared 1 h after injection with HN2 to minimize the effect of subsequent repair processes on the yield of lesions. For mice receiving HN2 alone, the greatest level of cross-linking was found in spleen and jejunum, with the liver showing the lowest level. In animals that had been pretreated with MISO (1 mg g-1, i.p.) for 0.5 h prior to injection with HN2, the amount of cross-linking in the spleen and jejunum was not affected by MISO; however, in all other tissues that were examined, cross-linking was enhanced by MISO to a varying extent depending on the specific tissue. The greatest enhancement was observed in the liver (X 6) and kidney (X 3.1), both of these tissues showing a greater enhancement than either of the two fibrosarcomas. The potentiation of HN2 cross-linking in a particular tissue correlated well with two cellular processes that are known to be nitroreduction-dependent in vitro, namely, the degree of MISO-induced GSH depletion and the binding of MISO to cellular macromolecules. Thus, the potentiation of cross-linking in normal tissues such as liver and kidney, and by inference in tumours, may be intimately related to the generation and/or accumulation of nitro-reduced MISO metabolites in those tissues.
Insights
Misonidazole (MISO) enhances DNA cross-linking by nitrogen mustard (HN2) in various mouse tissues, particularly liver and kidney. This potentiation is linked to MISO
Area of Science:
- Pharmacology
- Molecular Biology
- Oncology
Background:
- DNA cross-linking agents like nitrogen mustard (HN2) are used in cancer therapy.
- Misonidazole (MISO) is a hypoxic cell radiosensitizer.
- Understanding drug interactions is crucial for optimizing cancer treatment.
Purpose of the Study:
- To investigate the effect of MISO on HN2-induced DNA cross-linking in vivo.
- To determine tissue-specific variations in this interaction.
- To explore the mechanisms underlying MISO's influence on DNA cross-linking.
Main Methods:
- Alkaline elution technique for DNA cross-link analysis.
- In vivo treatment of C3H mice with HN2 and MISO.
- Tissue sample preparation 1 hour post-HN2 injection to assess initial cross-linking.
Main Results:
- HN2 alone caused maximal cross-linking in spleen and jejunum, minimal in liver.
- MISO pretreatment did not affect cross-linking in spleen and jejunum.
- MISO significantly enhanced HN2-induced cross-linking in liver (6-fold) and kidney (3.1-fold).
- Potentiation correlated with MISO-induced GSH depletion and macromolecular binding, suggesting nitroreduction-dependent mechanisms.
Conclusions:
- MISO potentiates HN2-induced DNA cross-linking in a tissue-specific manner.
- The enhancement is likely mediated by nitro-reduced MISO metabolites.
- These findings have implications for combination therapies involving MISO and DNA cross-linking agents.
More Related Videos
10:38In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
12:15Quantification of three DNA Lesions by Mass Spectrometry and Assessment of Their Levels in Tissues of Mice Exposed to Ambient Fine Particulate Matter
Published on: May 29, 2019